Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01239693
Other study ID # iLiNS-DYAD-M
Secondary ID
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date February 2011
Est. completion date March 31, 2025

Study information

Verified date November 2023
Source Tampere University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The use of lipid-based nutrients (LNS), such as Nutributter or fortified spread (FS), have been associated with improved growth and development outcomes among infants in Ghana and Malawi. Modified versions of such supplements have been developed to improve their nutrient density and quality and to lower their costs. Such modified products have proven acceptable to pregnant women in Malawi and Ghana. In the present trial, the investigators aim to test the effect of LNS on pregnancy and child outcomes, when given during pregnant and lactating women and their infants from 6 to 18 months of age. In control groups, participants will receive either iron+folate tables during pregnancy only or multiple micronutrient tablets during pregnancy and first six months of lactations. The main hypothesis to be tested suggests that the mean length-for-age Z-score (LAZ) of 18-month-old infants who received LNS between 6 and 18 months of age and whose mothers were provided with LNS during pregnancy and the first 6 months of lactation is higher than the mean LAZ score of same age infants who received no dietary supplements and whose mothers received iron-folate supplementation during pregnancy only. To detect the long-term effect of the LNS supplementation, we now propose to conduct a follow-up study when the children are 9 years old, to see if the intervention had effect on children's growth, cardiometabolic and respiratory status and neurocognitive development.


Description:

Pregnant women will be identified from the antenatal clinics of 4 governmental and 2 other health centres. A total of 1400 women meeting set criteria will be randomised into receiving one of the following interventions: 1) Iron and folic acid supplementation to the mother during pregnancy only (IFA group), 2). Multiple micronutrient supplementation to the mother during pregnancy and six months thereafter (MMN group), 3) Lipid-based nutrient supplements to the mother during pregnancy and six months thereafter and to the child from 6 to 18 months of age (LNS group). The mothers will receive LNS or the multiple micronutrients at 2-weekly intervals at their homes during pregnancy and weekly during first six months of lactation. Children in the LNS group will receive LNS weekly, starting at 6 months. Mothers will be medically examined and tested for defined laboratory parameters at enrolment, at 36 gestation weeks, at birth or soon thereafter, and at 6 months after delivery. Child size will be assessed at birth or soon thereafter and at 3, 6, 12, and 18 months of age. The mothers will undergo a morbidity evaluation fortnightly and the children weekly. 864 mother-infant pairs will undergo the complete intervention and follow-up, as described above. The remaining 536 participants will undergo a simplified intervention and follow-up, in which there are no interventions after birth and the child follow-up consists only of 4 3 health centre and one home visits; first at 1 week, then at six weeks (at home) and at 6 and 18 months of age. A sub-study on the the development of intestinal microbiome was added in August 2011. This entails the collection of stool samples from the mother at 1 month after delivery, breast milk samples from the mothers at 1, 3, and 6 months after delivery and stool and urine samples from the children repeated during the a8 months of intervention. The aim of this subproject is to study the development of the infants' intestinal microbiota, its predictors and its association to child growth and other health outcomes. At the same time point, the sample size was reduced from 2400 to 1400 participants (due to constraints in funding). A one year post-intervention follow-up for participants in the complete follow-up was added to the study protocol in August 2013. The intervention will be stopped when the participants are 18 months old. Thereafter, there will be an anthropometrirc assessment and blood and urine draw at the study clinic at 24 and 30 months of age. Stool samples will be collected from the participants at the age of 21, 24, 27 and 30 months, to study the development of intestinal microbiome. In a follow-up study, when the children are 10 years old, we will assess: 1. child growth using standard anthropometric measures, 2. cardiometabolic health by measuring body composition, blood pressure and plasma lipids, 3. neurodevelopment by measuring neural function, cognitive skills and education attainment using EE and EGMA and Raven's questionnaires, 4. lung function with spirometry and allergy symptoms and asthma using ISAAC questionnaire.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 1391
Est. completion date March 31, 2025
Est. primary completion date April 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 15 Years and older
Eligibility Inclusion Criteria: - Ultrasound confirmed pregnancy of no more than 20 completed gestation weeks - Permanent resident of Mangochi District Hospital, Malindi Hospital or Lungwena Health Centre catchment areas - Availability during the period of the study - Signed informed consent Exclusion Criteria: - Less than 15 years of age - Need for frequent medical attention due to a chronic health condition - Diagnosed asthma treated with regular medication - Severe illness warranting hospital referral - History of allergy towards peanuts - History of anaphylaxis or serious allergic reaction to any substance, requiring emergency medical care - Pregnancy complications evident at enrolment visit (moderate to severe oedema, blood Hb concentration < 5 g / dl, systolic blood pressure (BP) > 160 mmHg or diastolic BP > 100 mmHg) - Earlier participation in the iLiNS-DYAD-M trial - Concurrent participation in any other clinical trial

Study Design


Intervention

Dietary Supplement:
IFA
Women during pregnancy: 1 tablet of iron+ folate daily until delivery (60 mg iron + 400 ug folic acid) Women during lactation (from delivery to 6 months post-partum): 1 daily tablet of calcium (200 mg), akin to placebo Children from 6 to 18 months of age: None
MMN
Women during pregnancy: 1 tablet of multiple micronutrients daily until delivery Women during lactation (from delivery to 6 months post-partum): 1 daily tablet of multiple micronutrients Children from 6 to 18 months of age: None
LNS
Women during pregnancy: 1 sachet of LNS-P&L (20 g of LNS) daily until delivery Women during lactation (from delivery to 6 months post-partum): 1 daily sachet of LNS-P&L (20 g of LNS) Children from 6 to 18 months of age: 2 daily sachet of LNS-20gM (20 g of LNS)

Locations

Country Name City State
Malawi University of Malawi, College of Medicine Mangochi

Sponsors (6)

Lead Sponsor Collaborator
Tampere University Bill and Melinda Gates Foundation, Finnish Institute for Health and Welfare, Kamuzu University of Health Sciences, University of California, Davis, University of Oulu, Finland

Country where clinical trial is conducted

Malawi, 

Outcome

Type Measure Description Time frame Safety issue
Primary Birth weight approx 20 weeks after enrollment (within 48 hours)
Primary Newborn length At 1 week of age
Primary Length for age Z-score (LAZ) at 18 months of age 12 months after enrollment (age 18 months)
Secondary Anthropometric status (weight, BMI, mid upper arm circumference and triceps and sub-scapular skin-fold thickness) at ~ 36 wk gestation and 6 months postpartum
Secondary Gestational age at delivery, proportion of preterm deliveries At delivery
Secondary Proportion of low birth weight babies At birth
Secondary Anaemia and iron status (Hb, ZPP, transferrin receptor), other micronutrient status (vitamin A, B-vitamins, zinc), malarial antigen At ~ 36 wk gestation and 6 mo postpartum
Secondary Red blood cell essential fatty acid status At ~ 36 wk gestation
Secondary Urinary iodine At ~ 36 wk gestation
Secondary Total plasma cholesterol concentration At ~ 36 wk gestation
Secondary Basal salivary cortisol concentration At ~ 28 and ~ 36 wk gestation
Secondary Blood pressure At 36 wk gestation
Secondary Breast milk composition (essential fatty acids, vitamin A, B-vitamins) At 6 mo postpartum
Secondary Depressive symptoms (which may be related to essential fatty acid status) At 4 weeks and at 6 months postpartum
Secondary Incidence of febrile malaria episodes During pregnancy
Secondary Peripheral blood malaria parasitaemia At 32 wk gestation and at delivery
Secondary Placental malaria histology At delivery
Secondary Evidence of defined bacteria in the chorionic membranes at delivery (quantitative DNA amplification method) At birth
Secondary Prevalence of Neisseria gonorrhoea, Chlamydia trachomatis, in swab samples taken from maternal uterine cervix(qualitative DNA amplification method) At one week after delivery
Secondary Prevalence of bacterial vaginosis, Trichomonas vaginalis, or candidiasis, in swab samples taken from maternal vagina(direct microscopy) At one week after delivery
Secondary Malaria immunity At enrolment, at ~ 36 wk gestation, and 6 months post-partum
Secondary Anthropometric infant status (weight, length, head circumference and mid upper arm circumference) At 7 days of age and at 6, 12 and 18 months of age. After the intervention at 24 and 30 months and at 10 y of age.
Secondary Infant anaemia and iron status (Hb, ZPP), micronutrient (vitamin A, B-vitamins) and essential fatty acids status, evidence of acute inflammation (CRP, AGP), and malarial antigen and microscopy At 6 and 18 months of age
Secondary Incidence of neonatal hospitalizations At or before age 28 days
Secondary Clinical morbidity Between 0 and 18 months of age
Secondary Child feeding practices and maternal report of child sleep patterns At 6, 12 and 18 months of age
Secondary Antibody response to measles vaccination At 18 months of age
Secondary Malaria immunity At 6 and 18 months of age
Secondary Basal salivary cortisol concentration At 6, 12 and 18 months of age
Secondary Cortisol response to acute stress At 6 and 18 months of age
Secondary Achievement of five motor milestones and four other developmental milestones From 0 to 18 mo
Secondary Neurobehavioral development At 18 months of age
Secondary Incidence of serious adverse events During pregnancy and 18 months of infant follow-up
Secondary Prevalence of maternal periodontitis At one week after delivery
Secondary Maternal cognition Measured with several different tests 6 months after delivery
Secondary Mother - child interaction Measured with a number of observational tests and questionnaires 6 months after delivery
Secondary The composition of intestinal microbiota Done with 16s sequencing, from stored stool samples 1, 2, 3, 4, 5, 6, 9, 12, 15, 18, 21, 24, 27, and 30 months of child age
Secondary diastolic blood pressure Mobil-o-Graph blood pressure monitoring system Child is 10 years
Secondary central blood pressure Mobil-o-Graph blood pressure monitoring system Child is 10 years
Secondary pulse rate Mobil-o-Graph blood pressure monitoring system Child is 10 years
Secondary vascular resistance Mobil-o-Graph blood pressure monitoring system Child is 10 years
Secondary plasma concentration of glucose Cobas c702 machine Child is 10 years
Secondary plasma concentration of cholesterol Cobas c702 machine Child is 10 years
Secondary plasma concentration of HDL/LDL cholesterol Cobas c702 machine Child is 10 years
Secondary plasma concentration of triglycerides Cobas c702 machine Child is 10 years
Secondary plasma concentration of c-reactive protein Cobas c702 machine Child is 10 years
Secondary plasma concentration of alkaline phosphatase Cobas c702 machine Child is 10 years
Secondary plasma concentration of aspartyl alanine transferase Cobas c702 machine Child is 10 years
Secondary plasma concentration of potassium Cobas c702 machine Child is 10 years
Secondary plasma concentration of sodium Cobas c702 machine Child is 10 years
Secondary plasma concentration of urate Cobas c702 machine Child is 10 years
Secondary Spirometry measures functional volume of the lungs Global Lung Function Initiative standards, Medikro pro spirometry Child is 10 years
Secondary asthma symptoms ISAAC questionnaire Child is 10 years
Secondary allergy symptoms ISAAC questionnaire Child is 10 years
Secondary neural functioning EEG Child is 10 years
Secondary processing speed EEG Child is 10 years
Secondary oculomotor reaction time eye-tracking Child is 10 years
Secondary academic achievement Early Grade Mathematics Assessment, EGMA Child is 10 years
Secondary height Child is 10 years
Secondary sitting height Child is 10 years
Secondary weight Child is 10 years
Secondary head circumference Child is 10 years
Secondary mid-upper arm circumference Child is 10 years
Secondary body composition Tanita MC-780 MAS Child is 10 years
See also
  Status Clinical Trial Phase
Completed NCT01341236 - Near Infrared Spectroscopy (NIRS) and Superior Mesenteric Artery (SMA) Doppler Patterns as Predictor of Feeding Tolerance in Very Low Birth Weight (VLBW) IntraUterine Growth Restricted (IUGR) and NON IUGR Infants Phase 4
Completed NCT03533712 - Effect of a Fortified Balanced Energy-Protein Supplement on Birth Outcome and Child Growth in Houndé District, Burkina Faso. Phase 4
Active, not recruiting NCT05108675 - Microbiome and Malnutrition in Pregnancy (MMiP)
Completed NCT03040375 - Integrating Infant Feeding Counselling With Psychosocial Stimulation to Improve Child Growth and Development in Urban Slum of Bangladesh N/A
Recruiting NCT06207071 - Early DHA/ARA Supplementation in Growth-restricted Very Preterm Infants: A Randomized Clinical Trial N/A
Recruiting NCT06405360 - DEUX OEUFs: Cracking the Potential of Eggs to Improve Child Growth and Development N/A
Completed NCT02098031 - Improving the Nutrition Status of Infants in South-Western Uganda N/A
Completed NCT02755012 - Impact of Maternal Stress on Infant Stunting N/A
Completed NCT01333995 - Peer Conselling Infant Feeding Education Program N/A
Completed NCT05584969 - Peer Groups to Improve Infant Feeding Practices and Child Growth in Post-emergency Settlements in Uganda N/A
Completed NCT03385252 - The Mazira Project: An Evaluation of Eggs During Complementary Feeding in Rural Malawi N/A
Completed NCT04252807 - A Common Elements-based Intervention to Improve Maternal Psychological Well-being and Mother-infant Interaction N/A
Completed NCT03181178 - Effect of a Complementary Food Supplement on Growth and Morbidity of Ghanaian Infants N/A
Active, not recruiting NCT04504617 - Nutrition Education Intervention to Enhance Complementary Feeding Practices Among Infants in Southern Ethiopia N/A